Last Updated: July 12, 2026

Claims for Patent: 11,744,832

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,744,832

Title:	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	James D. Rodgers, Stacey Shepard
Assignee:	Incyte Corp , Incyte Holdings Corp
Application Number:	US17/689,510
Patent Claims:	1. A method of treating graft versus host disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the composition is suitable for oral administration and for providing sustained release of the compound or the salt. 2. The method of claim 1, wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the composition is a unit dosage form. 4. The method of claim 3, wherein the unit dosage form is a tablet. 5. The method of claim 3, wherein the unit dosage form is a capsule. 6. The method of claim 3, wherein the unit dosage form further comprises an enteric coating. 7. The method of claim 3, wherein the unit dosage form comprises from about 5 to about 1000 mg of the compound or the salt. 8. The method of claim 2, wherein the composition further comprises one or more excipients selected from lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. 9. The method of claim 2, wherein the composition further comprises microcrystalline cellulose. 10. The method of claim 2, wherein the composition further comprises lactose. 11. The method of claim 2, wherein the composition further comprises microcrystalline cellulose and lactose.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.